In canine coronary artery preparations, the proteinase-activated receptor-2 (PAR2) activating peptides (PAR2-APs) SLIGRL-NH2 and 2-furoyl-LIGRLO-NH2 caused both an endothelium-dependent relaxation and an endothelium-independent contraction. Relaxation was caused at peptide concentrations 10-fold lower than those causing a contractile response. Although trans-cinnamoyl-LIGRLO-NH 2, like other PAR2-APs, caused relaxation, it was inactive as a contractile agonist and instead antagonized the contractile response to SLIGRL-NH 2. RT-PCR-based sequencing of canine PAR 2 revealed a cleavage/activation (indicated by underlines) sequence (SKGR/SLIGKTDSSLQITGKG) that is very similar to the human PAR2 sequence (R/SLIGKV). As a synthetic peptide, the canine PAR-AP (SLIGKT-NH2) was a much less potent agonist than either SLIGRL-NH2 or 2-furoyl-LIGRLO-NH2, either in the coronary contractile assay or in a Madin-Darby canine kidney (MDCK) cell PAR2 calcium signaling assay. In the MDCK signaling assay, the order of potencies was as follows: 2-furoyl-LIGRLO-NH 2 Ͼ Ͼ SLIGRL-NH2 ϭ trans-cinnamoyl-LIGRLO-NH 2 Ͼ Ͼ SLIGKT-NH2, as expected for PAR 2 responses. In the coronary contractile assay, however, the order of potencies was very different: SLIGRL-NH 2 Ͼ Ͼ 2-furoyl-LIGRLO-NH2 Ͼ Ͼ SLIGKT-NH 2, trans-cinnamoyl-LIGRLO-NH2 ϭ antagonist. Because of 1) the distinct agonist (relaxant) and antagonist (contractile) activity of trans-cinnamoyl-LIGRLO-NH 2 in the canine coronary contractile assays, 2) the different concentration ranges over which the peptides caused either relaxation or contraction in the same coronary preparation, and 3) the markedly distinct structure-activity profiles for the PAR-APs in the coronary contractile assay, compared with those for PAR 2-mediated MDCK cell calcium signaling, we suggest that the canine coronary tissue possesses a receptor system for the PAR-APs that is distinct from PAR 2 itself.
tors cloned to date (PAR 1 to PAR 4 ) has a distinct tethered ligand sequence. PAR 1 , PAR 2 , and PAR 4 can be activated selectively by short synthetic peptides based on their tethered ligand sequences, without the need for proteolysis. Such PARselective agonists [so-called PAR-activating peptides (PARAPs)] are of considerable value in assessing the consequences of PAR activation in a variety of tissues, both in vitro and in vivo, in lieu of proteolytic receptor activators that would yield confounding results because of their lack of receptor specificity (11, 12, 14) . In particular, the PAR 2 -APs SLIGRL-NH 2 , transcinnamoyl-LIGRLO-NH 2 , and 2-furoyl-LIGRLO-NH 2 have proved to be the most potent receptor-selective activators of PAR 2 from a number of species, including rats, mice, guinea pigs, and humans. The N-acyl derivatives were designed to be aminopeptidase resistant for use in vivo and in vitro. In murine, rat, and human tissues, the 2-furoyl derivative is 10 -100 times more potent for activating PAR 2 than either SLIGRL-NH 2 or trans-cinnamoyl-LIGRLO-NH 2 , which are about equipotent in activating PAR 2 in all species so far examined (15, 23) .
In vascular tissue, the endothelium is the principal target for PAR 2 -APs, which in preconstricted preparations cause an endothelium-dependent relaxation that is both nitric oxide mediated and nitric oxide independent (endothelium-derived hyperpolarization factor-like) (22) . Although PAR 2 mRNA is present in endothelium-denuded rat aorta tissue, we have been unable to detect a response (contraction or relaxation) to PAR 2 activation in such preparations (3, 4, 30) . That said, we have detected receptors distinct from PAR 2 that can mediate contractile responses caused by PAR 2 -APs in murine (21) and human (31) vascular tissues by a mechanism that may or may not involve the release of an endothelium-derived contracting factor (31) . Specifically, in murine mesenteric arteries, the PAR 2 -AP trans-cinnamoyl-LIGRLO-NH 2 is able to cause an endothelium-independent contractile response in PAR 2 -null mice, pointing to a novel non-PAR 2 vascular contractile receptor for this peptide (21) . Thus the PAR 2 -APs themselves can serve as probes to activate and discover receptors other than PAR 2 .
We turned to the canine coronary artery as a potential model vascular preparation for understanding the non-PAR 2 receptor(s) responsible for the contractile actions of PAR 2 -APs. This preparation has long been used to evaluate the vasoregulatory properties of thrombin, presumably acting via PAR 1 (7, 8, 32, 36) . No such studies related to the potential consequences of PAR 2 activation in the canine coronary have yet been described, although a role for PAR 2 has been suggested for other canine tissue targets like the pancreas and kidney (26, 29) . It was our aim, therefore, to evaluate the potential role of PAR 2 in regulating canine coronary contractility and to determine whether a receptor other than PAR 2 might be involved in the actions of PAR 2 -APs in this tissue. To this end, we used the potent and receptor-selective PAR 2 -APs SLIGRL-NH 2 , transcinnamoyl-LIGRLO-NH 2 , and 2-furoyl-LIGRLO-NH 2 , all of which have been validated as PAR 2 probes for vascular preparations in previous work (3, 12, 14, 15, 23) . These peptides are known not to activate PAR 1 or PAR 4 from many species at concentrations up to 200 M or higher (14, 22) . We also determined by an RT-PCR sequencing approach the partial cleavage/activation sequence of canine PAR 2 , so as to identify its tethered-ligand-derived sequence and thereby synthesize and test SLIGKT-NH 2 as a canine receptor-derived PAR 2 -AP. The PAR 2 -APs were used in both endothelium-intact and endothelium-denuded canine coronary ring preparations to obtain a structure-activity relationship (SAR) profile for the contractile and relaxant activities of the agonists. This SAR profile was compared with the one obtained for calcium signaling by the same PAR 2 -APs in PAR 2 -expressing cultured MDCK cells, which represent a well-characterized readily studied system that responds to PAR 2 activation. Because presently there are no commercially available high-potency receptor-selective PAR 2 antagonists, we relied principally on the hypothesis that, according to SAR principles established in the past for adrenoceptors (2), distinct SAR agonist profiles for the agonist PAR 2 -APs in the contractile and relaxant tissue bioassays, compared with the SAR profile in the PAR 2 -mediated MDCK calcium signaling assay, would distinguish PAR 2 from non-PAR 2 -mediated responses in the canine coronary.
MATERIALS AND METHODS

Test Systems Used
Canine coronary tissues. This study was performed with the cooperation of Dr. J. V. Tyberg, University of Calgary Cardiovascular Research Group, using mongrel dogs (18 -20 kg) of either sex and procedures previously described (9) . This cooperation, in which animals used for nondrug studies of cardiovascular hemodynamics by the Tyberg laboratory were used jointly for the coronary studies, enabled an efficient and economical use of this valuable resource of canine tissues.
All experiments were done according to a protocol approved by the faculty Animal Care Committee of the University of Calgary, in keeping with the Canadian Council on Animal Care. All animal experiments also conformed to the Guiding Principles for Research Involving Animals and Human Beings of the American Physiological Society. The same principles were followed for experiments done with animals obtained in Suresnes, wherein animals dedicated for the study were used.
Animals were euthanized by a lethal injection of KCl, and the heart was removed for isolation of the left descending coronary artery. The coronary and other vascular tissues were carefully trimmed free of adipose and connective tissue and were either used immediately or were stored overnight at 4°C in a 25 mM HEPES-fortified isotonic Krebs-Henseleit buffer of the following composition (in mM): 115 NaCl, 4.7 KCl, 2.5 CaCl 2, 1.2 MgCl, 25 NaHCO3, 1.2 KH2PO4, and 10 glucose, adjusted to pH 7.4. Comparable samples of coronary, renal, and femoral artery tissues were obtained. On the day of an experiment, endothelium-intact arterial rings (5 mm ϫ 2 mm) were cut for use in the organ bath. Because the PARs are regulated by proteolysis (either activated or disarmed), it was not possible to use tissue dissociation methods to assess the action of the PAR-APs in freshly detached cells from the tissues.
Cell culture. Epithelial Madin-Darby canine kidney (MDCK) cells (American Type Culture Collection, Manassas, VA) were cultured in 75-cm 2 plastic T-flasks (NUNC, VWR International, Mississauga, ON) at 37°C using DMEM (GIBCO, Grand Island, NY) supplemented with 10% FCS under a humidified atmosphere of 5% CO 2 in room air. These cells offer the advantage that, unlike other caninederived cultures, the cells are readily released from the culture surface without the use of trypsin and can be easily "loaded" with calcium indicator dye (fluo 3) for the study of calcium signaling in cell suspensions. For studies of PAR 2-stimulated increases in intracellular calcium, cells were propagated without the use of trypsin by resuspension in EDTA-containing isotonic PBS (cell dissociation buffer, enzyme-free; GIBCO).
Measurements Made
Monitoring contractile and relaxant responses. Arterial rings were suspended in a gassed (95% O2-5% CO2) plastic cuvette containing the above-described Krebs-Henseleit buffer without addition of HEPES (buffer volume 3.5 ml) under a resting tension of 1 g, which was found to be optimal for observing contractile responses in the preparations. Tissues were equilibrated in buffer for a minimum of 1 h before each experiment was started. Endothelial integrity (or lack thereof in denuded preparations) was verified by monitoring the presence or absence of a relaxant response to substance P (0.01-1 M) for rings that had been preconstricted with 1 M PGF 2␣. After changes in tension were monitored, using either Grass or Statham force-displacement transducers, the preparation was washed free of added reagents and reequilibrated in buffer for a minimum of 20 min before the addition of other test reagents.
Relaxant responses. The relaxant responses of PGF 2␣-preconstricted endothelium-intact preparations were monitored for a number of PAR-APs at concentrations in the range of 0.5-50 M. As indicated in RESULTS, the variability in the relaxation response to the same peptides from one preparation to another precluded measurements of reliable concentration-response curves. Thus only representative responses are shown, reflecting comparable observations made in four or more independently prepared coronary preparations.
Contractile responses and measurements of antagonism by transcinnamoyl-LIGRLO-NH 2. The main focus of our study was on the reproducible contractile responses caused by the PAR2-APs. Tissues at baseline tension (1.0 g) were exposed to increasing concentrations of the PAR 2-APs, and tension was allowed to reach a plateau, at which time a wash procedure removed all agonists from the tissue bath and the tissue was reequilibrated for 20 min between exposure to agonists. To construct concentration-effect curves for evaluating the SAR of the peptide agonists, responses to increasing concentrations of each peptide were expressed as a percentage (%KCl) of the contraction caused in the same tissue by 50 mM KCl. At each peptide concentration evaluated, data from four or more independently prepared tissue preparations were pooled. Data points for the concentration-contraction curves represent the averages Ϯ SE for pooled measurements. To assess the ability of trans-cinnamoyl-LIGRLO-NH 2 to antagonize the contractile action of SLIGRL-NH2, tissues were first exposed to 50 M SLIGRL-NH2 and a contractile response was measured. After the tissue was washed free of peptide and reequilibrated in fresh buffer for 20 min, the preparation was treated for 10 min with a predetermined concentration of trans-cinnamoyl-LIGRLO-NH 2, and the reduced response to the addition of 50 M SLIGRL-NH2 in the continued presence of trans-cinnamoyl-LIGRLO-NH2 was again measured. The contractile response of the tissue in the presence of trans-cinnamoyl-LIGRLO-NH2 was then expressed as a percentage (%control) of the response to SLIGRL-NH2 in the absence of trans-cinnamoyl-LIGRLO-NH2. Measurements done with a minimum of four independently prepared coronary rings were obtained for increasing concentrations of trans-cinnamoyl-LIGRLO-NH 2. Data are plotted as means Ϯ SE for observations at each concentration of trans-cinnamoyl-LIGRLO-NH2. To minimize the effect of nitric oxide, tissues were treated with 0.1 mM nitro-Larginine methyl ester (L-NAME) before the addition of agonists to the organ bath. Measurements of the contractile responses to the PAR 2-APs and to the PAR1-AP TFLLR-NH2 were made in tissues that were maintained at 1-g resting tension, without preconstriction with PGF2␣.
Monitoring calcium transients. To evaluate the SARs for the PAR 2-APs in a recognized canine cell target that responds reliably to PAR2 activation, we used the increased intracellular calcium response of cultured MDCK cells. Measurements of increases in intracellular calcium triggered by PAR 2 activation, as monitored by increases in fluo 3 fluorescence at 530 nm (excitation wavelength of 480 nm), were done with cell suspensions as previously described in detail elsewhere (3, 14) . The fluorescence signals caused by the addition of test agonists [PAR-APs added to 2 ml of a cell suspension (final concentration of cells: ϳ1 ϫ 10 6 /ml in the above buffer)] were compared with the fluorescence peak heights yielded by replicate cell suspensions treated with 2 M of ionophore A-23187 (Sigma-Aldrich, St. Louis, MO). To construct concentration-response curves for fluorescence yield, the signals caused by the addition of each concentration of the test agonists (PAR 2-APs) were expressed as a percentage (%A-23187) of the fluorescence peak height yielded by replicate cell suspensions when treated with 2 M of the ionophore A-23187. This concentration of A-23187 was at the plateau of its concentrationresponse curve for a fluorescence response. Previous work (14) has shown that the fluorescence response of a cell preparation relative to 2 M A-23187 is a valid reference standard in the determination of concentration-response curves for all PAR agonists. Under these conditions, the calculated values for intracellular calcium in a variety of cultured cells were ϳ30 nM under basal conditions and ϳ340 nM on exposure to A-23187 (3, 13, 24) . In addition, in previous work, our group (14) observed, as expected, that the presence of PAR 2-APs in the cell suspensions does not affect the fluo 3 signal generated by the intracellular calcium indicator in response to other agonists such as lysophosphatidic acid.
Isolation of RNA, RT-PCR amplification of PAR 2 mRNA, and nucleotide sequencing of canine PAR2. Cellular RNA was isolated either from confluent cultures of MDCK cells or from quick-frozen isolated canine heart, lung, and intestinal tissues. Left anterior descending (LAD) coronary artery segments (3-5 cm long) were dissected free of adventitial connective tissue and trimmed before processing. A section of left ventricular tissue immediately adjacent to the LAD coronary was similarly processed. In brief, the tissue, quick-frozen in liquid nitrogen, was pulverized with a ceramic mortar and pestle and homogenized by passing through a QIAShredder (Qiagen, Mississauga, ON, Canada), and RNA was extracted from cell and homogenized tissue samples with an RNeasy kit (Qiagen) according to the manufacturer's instructions. MDCK cell and tissue cDNA was reverse transcribed at 37°C for 60 min using the firststrand cDNA synthesis kit (Pharmacia, Uppsala, Sweden) or the omniscript RT kit (Qiagen) according to the manufacturer's recommendations.
To determine the canine receptor sequence, the RT product from the MDCK cells was used for PCR amplification to determine a full-length receptor cDNA with overlapping primer pairs flanking the entire coding region. The primer pairs were originally designed on the basis of the published rat PAR 2 sequence (30) . The sequence of the receptor representing the "cleavage/activation" domain containing the "tethered ligand" was determined with the following primer pair: 5Ј-TCAAGCTTCCACCATGCGAAGTCTCAGCCTGGC-3Ј was the forward primer for PAR2 (containing a HindIII site and Kozak sequence shown in bold) and 5Ј-CCCGGGCTCAGTAGGAGGTTT-TAACAC-3Ј was the PAR 2 reverse primer (containing SmaI site shown in bold). For a semi-quantitative estimate of the relative abundance of mRNA for PAR 1 and PAR2 in the tissue samples, we used primer pairs that were targeted to comparable regions of the two receptors. For PAR 1, the primer pair was AGTGCTCCCCTTCAA-GATCA (forward) and AGGGTTTCATTGAGCACGTC (reverse), with expected PCR product size of 327 bp. For PAR 2, the second set of primer pair used for this purpose was CTTGGCAGACCTCCTT-TCTG (forward) and ATAGCAGGAGAGCGGAGTGT (reverse), with expected PCR product size of 467 bp. The RT-PCR products for the two PARs were compared with the RT-PCR product for ␤-actin in the same samples. The primer pair used for actin was GGGTCA-GAAGGATTCCTATG (forward) and GGTCTCAAACATGATCT-GGG (reverse), with an expected PCR product size of 237 bp.
Routinely, amplification was done with 2.5 U of Taq DNA polymerase [Promega (Madison, WI) or Qiagen] in a 10 mM Tris⅐HCl buffer, pH 9.0 (final volume of 50 l), containing 1.5 mM MgCl 2, 50 mM KCl, 0.1% (vol/vol) Triton X-100, and 0.2 mM of each dNTPs. Amplification was allowed to proceed for 35 cycles beginning with a 1-min denaturing period at 94°C, followed by a 1-min reannealing time at 55°C, and a primer extension period of 2 min at 72°C.
The PCR products, analyzed along with a standard size oligonucleotide "ladder" mix (Mass Ruler, Fermeutas, Burlington, ON, Canada), were separated by 1.5% agarose gel electrophoresis and visualized with ethidium bromide. Images of the gels were acquired with a gel documentation system (Bio-Rad) and the Quantity One image acquisition software (Bio-Rad). Intensities of bands were determined by densitometry analysis using the NIH ImageJ image processing software, and signals of the RT-PCR products for the two PARs were expressed relative to the signal for ␤-actin in the same sample (see Fig. 7 ). The identities of the RT-PCR products from the MDCK cell source and the tissue sources were verified by automated DNA sequencing methods conducted by the University Core DNA Services at the University of Calgary Faculty of Medicine and confirmed to be in agreement with the canine PAR sequences.
Drugs, Chemical Reagents, and Other Materials
All peptides, including the PAR 2 peptide antagonist LIGK-NH2, were synthesized as carboxy-amides (Ͼ95% purity, assessed by HPLC and mass spectrometry) by the Peptide Core Facility at the University of Calgary (peplab@ucalgary.ca). The PAR 2 peptide antagonist LIGK-NH2 (ENMD 1005) was kindly provided by EntreMed (Rockville, MD), courtesy of Dr. Todd Hembrough. Unless otherwise indicated, all remaining chemicals, including substance P, neurokinin A, L-NAME, and PGF2␣, were purchased from Sigma-Aldrich, as was the neurokinin-2 (NK2)-tachykinin receptor antagonist cyclo(QWF-GLM) (L-659,877). The neurokinin-1 (NK1)-receptor antagonist GR-82334 was from Cedarlane Laboratories (Hornby, ON, Canada). Peptides as stock solutions of 1 mM or greater were dissolved in PBS containing 25 mM HEPES (pH 7.4). 4-Amino-5(4-methylphenyl)-7-(t-butyl)pyrazolo [3,4-D] pyrimidine (PP1) was from Calbiochem (La Jolla, CA).
Data Analyses and Statistical Procedures
Presented values represent the averages (ϮSE) of three or more measurements made with two or more independently grown cell culture crops or with four or more isolated vascular rings derived from several different animals. In figures, error bars are not shown when the magnitude of the error bar is smaller than the size of the symbols used to represent the data.
RESULTS
Relaxant and Contractile Responses in Coronary Artery Rings: Agonist and Antagonist Actions of trans-Cinnamoyl-LIGRLO-NH 2
Relaxant actions. Our first aim was to assess the relaxant and contractile actions of the PAR-APs in the bioassay. Similar to substance P (0.01-1 M), the PAR 2 peptide agonists transcinnamoyl-LIGRLO-NH 2 , SLIGRL-NH 2 , and 2-furoyl-LI-GRLO-NH 2 all caused a relaxant response in rings that had been precontracted with PGF 2␣ (Fig. 1, left; data not shown for 2-furoyl-LIGRLO-NH 2 ). At concentrations (50 M) 10-fold higher than those used for trans-cinnamoyl-LIGRLO-NH 2 and SLIGRL-NH 2 , the canine-derived PAR 2 -tethered ligand sequence (SLIGKT-NH 2 ) failed to cause a relaxant response, presumably because of its low biological potency (see below). For reasons we could not ascertain, although we observed a relaxant response to substance P in all preparations examined, there was considerable variation among different tissues in the ability of the PAR 2 agonists to cause relaxation in otherwise substance P-responsive tissues. In our preliminary series of 15 separate experiments with LAD coronary arterial tissues coming from different mongrel dogs of both sexes, a relaxation response to SLIGRL-NH 2 was observed in only six tissues. The responses of acutely isolated tissues were as variable as were tissues that were stored in the refrigerator in buffered saline overnight before the preparation of the rings for the assay. There was no correlation between the sex of the animal and the absence of relaxant response to the PAR 2 -APs. We were unable to determine the cause of this variability and therefore were not able to obtain reliable concentration-relaxation response curves for several PAR 2 agonists. Notwithstanding, on four or more occasions, we did observe relaxant response to the PAR 2 -APs tested, as shown by the representative tracings in Fig. 1 for SLIGRL-NH 2 and trans-cinnamoyl-LIGRLO-NH 2 . In contrast, the selective PAR 1 -AP TFLLR-NH 2 , which routinely elicited a contractile response at baseline tension (see below), uniformly failed to cause relaxation in tissues that otherwise relaxed in response to SLIGRL-NH 2 (Fig. 1C) . In preparations that did relax in response to repeated exposures to both substance P and SLIGRL-NH 2 , L-NAME did not affect the relaxant response to either agonist (not shown). Nonetheless, to eliminate any potential effect of endothelialderived nitric oxide in the preparations, we treated the tissues with L-NAME when we went on to assess the ability of the peptides to cause a contractile response (see Contractile actions). Given the lack of consistency of the relaxant assay and because our primary aim was to study the pharmacology of the PAR 2 -AP-induced contractile response, we did not evaluate the relaxant assay further and turned our attention to study the contractile assay.
Contractile actions. To assess the ability of the PAR 2 agonists to cause a contractile response, tissues were, as mentioned above, first treated with L-NAME to eliminate any potential production of nitric oxide, followed by exposure of the tissue to the peptide agonists. At baseline tension, SLIGRL-NH 2 (but not the partial reverse peptide LSIGRL-NH 2 ; not shown) elicited a contractile response, whereas the aminopeptidaseresistant PAR 2 -AP trans-cinnamoyl-LIGRLO-NH 2 did not (Fig. 1, A and B, right) , even in preparations in which it did cause a relaxant response at comparatively low concentrations (Fig. 1A) . The contractile responses caused by SLIGRL-NH 2 in tissues used immediately after isolation from the heart were not different from the responses of coronary tissues that had been stored at 4°C overnight. Therefore, to conserve on the use of animals, tissues that had been stored overnight were used for much of the work. Unlike the variability of the relaxation response, SLIGRL-NH 2 regularly caused a contractile response in all tissues evaluated. The contractile response was reproducible on washing the preparation and repeatedly exposing the tissue to the peptide. At a concentration of 100 M, the PAR 2 -AP SLIGRL-NH 2 also caused a contractile response in the circumflex coronary artery and in preparations of the femoral and renal arteries either with or without an intact endothelium (data not shown); the carotid artery responded only minimally to the peptide at this concentration. The coronary artery tissue responded best to the peptides and was therefore used for further studies of the peptide structureactivity profiles.
Peptide structure-activity profiles. As shown by the concentration-effect curve for the LAD coronary artery, the contractile action of SLIGRL-NH 2 was maximal at ϳ50 M, with an EC 50 of ϳ15 M (Fig. 2) . The other PAR 2 -APs, including the canine PAR 2 -derived peptide SLIGKT-NH 2 , also caused a contractile response but with potency much lower than that of SLIGRL-NH 2 (Fig. 2) . The potency order of the PAR 2 -APs in the contractile assay was as follows:
Because of the lack of contractile activity of trans-cinnamoyl-LIGRLO-NH 2 , we wondered whether it might be an antagonist. Indeed, as shown by the representative tracing in Fig. 3 , top, when added first to the organ bath, this peptide was able to attenuate the contractile action of SLIGRL-NH 2 . A comparable antagonism of the contractile action of 2-furoyl-LIGRLO-NH 2 was also observed (not shown). In contrast, high concentrations (100 -200 M) of the partial reverse PAR 2 -derived peptide LSIGRL-NH 2 , which cannot activate PAR 2 and which did not cause a contractile response, did not block the contractile action of SLIGRL-NH 2 (not shown). The IC 50 for the ability of trans-cinnamoyl-LIGRLO-NH 2 to block the contractile action of 50 M SLIGRL-NH 2 was in the range of 30 -70 M (Fig. 3, bottom) . A comparable inhibitory potency for this peptide was found in both the anterior descending and circumflex arteries. In contrast, the peptide PAR 2 antagonist LIGK-NH 2 (ENMD 1005), which is not a partial agonist for PAR 2 , blocked the action of SLIGRL-NH 2 in a human embryonic kidney cell and MDCK cell calcium signaling assay (data not shown); however, unlike trans-cinnamoyl-LIGRLO-NH 2 , it did not affect the contractile action of SLIGRL-NH 2 in the coronary preparation (not shown). Thus, in the coronary artery tissue, the peptide trans-cinnamoyl-LIGRLO-NH 2 proved to be an agonist for endothelium-mediated relaxation but an antagonist for the contractile response generated at resting tension by SLIGRL-NH 2 . In contrast, SLIGRL-NH 2 was an agonist for both the relaxant and contractile responses. Furthermore, neither the PAR 2 -inactive peptide LSIGRL-NH 2 nor the PAR 2 -targeted peptide antagonist LIGK-NH 2 (ENMD 1005) was an agonist or an antagonist in the tissue.
Contractile Response Is Endothelium Independent, Enhanced by Indomethacin, and Not Dependent on Src Kinase Activity
Response to PAR 2 -AP. To evaluate the endothelium dependence of the contractile response, anterior descending coronary rings were denuded or not of the endothelium, as verified by the disappearance of a relaxant response to substance P, and tested for their contractile response to SLIGRL-NH 2 in the absence or presence of indomethacin (Fig. 4) . The contractile response was the same in either the presence or absence of the endothelium, and indomethacin potentiated the contractile response in the anterior descending preparation either with or without a functional endothelium (Fig. 4) . The enhanced contraction in the presence of indomethacin was observed in the two coronary preparations (anterior descending and circumflex) but not in the other arterial tissues studied (femoral, renal, and carotid; not shown). Because the presence or absence of the endothelium did not affect the contractile response, it was possible to use preparations either with or without an intact endothelium to assess the structure-activity profiles for the contractile responses.
Possible role of Src kinase. In view of work with G-proteincoupled agonist responses in porcine coronary and other vascular tissues wherein a contractile role for a tyrosine kinasedriven pathway has been identified (18, 34, 35) , we assessed the potential contribution of Src kinase by using the Srcselective kinase inhibitor PP1. This inhibitor did not affect the contractile action of SLIGRL-NH 2 (not shown), making it unlikely that Src plays a role in this response. 
Possible Action of PAR 2 -APs Via Neurokinin Receptors in Canine Coronary Tissue
During the course of our study, data were published suggesting that PAR 2 -related peptides, such as SLIGRL-NH 2 , can stimulate murine epithelial chloride secretion by activating the NK 1 receptor (1). In the coronary tissue assay, as shown in Fig.  1 , substance P presumably acting via the canine NK 1 receptor caused a relaxant and not a contractile response. In such preparations preconstricted by PGF 2␣ , exposure of the tissue to relatively high concentrations of SLIGRL-NH 2 (e.g., 50 -100 M) caused a further increase in tension, whereas the subsequent addition of substance P caused a prompt relaxation toward baseline (not shown). These data demonstrating diametrically opposed effects [on the one hand of relatively high concentrations of SLIGRL-NH 2 that caused contraction (50 -100 M), and on the other hand of low concentrations of substance P (0.01-1 M) that caused a relaxant response under the same conditions] indicated that the NK 1 receptor was not responsible for the contractile actions of SLIGRL-NH 2 . In accordance with this conclusion, the contractile action of SLIGRL-NH 2 was not affected by antagonists of the NK 1 , NK 2 , or the bradykinin B 1 /B 2 receptors (not shown).
Response to PAR 1 -AP
Although our main focus was on PAR 2 -APs, we also explored briefly the response of the coronary and other vascular preparations to the PAR 1 -AP TFLLR-NH 2 . In contrast to the relaxant action of the PAR 2 -AP in an endothelium-intact preparation, the PAR 1 -AP TFLLR-NH 2 , even at relatively low concentrations (0.5 M), caused contractile responses in the coronary preparation at baseline tension (data not shown) and an enhanced contractile response over and above the contraction caused by PGF 2␣ (Fig. 1C) . Comparable responses were observed in preparations either with or without an intact endothelium (not shown). At baseline tension, the PAR 1 -selective receptor AP (TFLLR-NH 2 ) caused a concentrationdependent contractile response in all arterial preparations that we examined (descending and anterior coronary, carotid, renal and femoral) (not shown). This contractile action of the PAR 1 -AP was the same in the absence or presence of 100 M trans-cinnamoyl-LIGRLO-NH 2 . Like the contraction caused by SLIGRL-NH 2 , the contraction induced by TFLLR-NH 2 was potentiated by indomethacin in the anterior descending coronary artery preparation (not shown). Also, like the SLIGRL-NH 2 -triggered contractile response, the response of the carotid artery preparation to TFLLR-NH 2 was minimal.
Calcium Signaling in Cultured MDCK Cells by PAR 2 -APs and Amino Acid Sequence of MDCK PAR 2
Structure-activity profile for PAR 2 -APs acting on canine PAR 2 in the calcium signaling assay. As outlined above, the endothelium-intact coronary preparation was not suitable for evaluating the canine SAR profile for the PAR 2 -APs. To assess the SAR profile for these peptides to activate PAR 2 , we therefore turned to a cultured MDCK cell calcium signaling assay. Although PAR 2 activation can stimulate a number of signal pathways in the MDCK cells (e.g., MAPK activation), the increase in intracellular calcium has proved to be a robust response suitable for studying the structure-activity profiles of PAR-APs in this and other cell types (14) . Our previous experience with isolated artery-derived smooth muscle cells indicated that they are not suitable for SAR studies because they do not release without enzymatic dissociation from the culture dish and do not readily permit studies of PAR activation in cell suspensions. In contrast, we found that cultured MDCK cells were ideal for our calcium signaling assay, thereby enabling a stringent evaluation of the structure-activity profile of the PAR 2 -APs for the canine receptor. In the MDCK cells, activation of PAR 2 with SLIGRL-NH 2 and the other PAR 2 -APs yielded a robust increase in intracellular calcium (Fig. 5) . In contrast, in MDCK cells in which PAR 2 was first completely desensitized by repeated exposure to SLIGRL-NH 2 so as to optimize visualizing the PAR 1 response, only a small signal was observed for TFLLR-NH 2 (Fig. 5, bottom right) at concentrations of 100 M. This concentration is well above concentrations known to activate PAR 1 maximally. Little or no calcium signal was observed at or below 50 M of TFLLR-NH 2 (not shown), although these concentrations might have triggered other responses in the cells, such as the activation of MAPK. No calcium signal to the PAR 4 -AP AYPGKF-NH 2 was observed (up to 300 M; not shown). Therefore, we were confident that the principal calcium signals observed in the MDCK assay in response to the PAR 2 -APs at concentrations below 50 M did not come from PARs other than PAR 2 and that the SARs derived from the calcium signaling measurements reflected accurately the activation of canine PAR 2 . Concentration-effect curves for calcium signaling in the MDCK cells (Fig. 6) showed that the relative potencies of the PAR 2 -APs in this assay were as follows: 2-furoyl-LIGRLO-NH 2 Ͼ Ͼ SLIGRL-NH 2 ϭ trans-cinnamoyl-LIGRLO-NH 2 Ͼ Ͼ SLIGKT-NH 2 , with EC 50 values estimated from the concentration-response curves of ϳ0.08, 0.8, and 10 M, respectively. We obtained the identical SAR for these peptides with a Kirsten virus-transformed rat kidney cell system expressing recombinant rat PAR 2 (Ref. 3 and data not shown). Unfortunately, attempts to clone and express the full-length canine PAR 2 construct to conduct similar experiments with expressed canine PAR 2 were not successful. Maximally, all of the PAR 2 -APs stimulated an elevation of intracellular calcium in the MDCK cells that was ϳ50% of the signal caused in the same cells by 2 M A-23187. This result, demonstrating the same maximal effect of all peptides, suggested that they were all "full agonists" in the MDCK PAR 2 calcium assay. Furthermore, the potency order of the PAR 2 -APs observed in the MDCK cells was not only the same for rat PAR 2 expressed in KNRK cells (above) but also for human PAR 2 expressed constitutively in cultured human embryonic kidney cells (data not shown and Ref. 14) .
Cloning and sequencing of canine PAR 2 . Given the presence of functional PAR 2 in the MDCK cells, we used them as a source of mRNA for RT-PCR-based sequencing of the canine receptor. This approach was a necessary prelude to assessing the content of PAR 2 mRNA in the coronary tissue. As shown in Table 1 , our data defined the tethered ligand sequence of MDCK PAR 2 (SLIGKT) that would be revealed by tryptic cleavage. That sequence was therefore used to probe the responsiveness of the canine tissue and the MDCK calcium assay (above). The cloning also established sequences for key portions of the canine receptor involved in signaling by either the tethered ligand or peptide agonists (extracellular loop 2 and intracellular loops 1, 2, and 3). The sequences that we determined matched exactly those deposited in the National Center for Biotechnology Information database (XM 546057) subsequent to the completion of this part of our study. As summarized in Table 1 , these sequences are very similar to the comparable sequences in human PAR 2 , particularly in the region of the cleavage-activation site (5) and are close to the same sequences that we determined in the past for rat PAR 2 (30) .
RT-PCR Detection of PAR 1 and PAR 2 mRNA in the Coronary and Other Canine Tissues
Given the responsiveness of the coronary preparation to the PAR-APs, it was of interest to establish the presence of PAR mRNA in the tissue. Analysis of the mRNAs for PAR 1 and PAR 2 detected by RT-PCR in the heart (coronary artery and ventricle), lung, and intestinal tissues is shown in Fig. 7 , relative to the RT-PCR signal for ␤-actin mRNA. The identity of the visualized RT-PCR products, which were of the expected size for the PARs, was confirmed by nucleotide sequencing. Although semi-quantitative, the data suggest that, relative to ␤-actin mRNA, there was an equivalent abundance of mRNA for PAR 1 and PAR 2 in the coronary, ventricular, intestinal, and lung tissue (Fig. 7) . Unequivocally, mRNAs for both PAR 1 and PAR 2 were present in the coronary tissues used for the bioassay procedures.
DISCUSSION
A main focus of our study was to determine the pharmacology of the coronary artery receptor(s) responsible for the contractile actions of the PAR 2 -APs. An evaluation of the structure-activity profile of these receptor APs for their effects is of general importance, since the biological responses to the PAR 2 -APs can be used (possibly uncritically) as evidence for a role for PAR 2 itself. Our group's previous work with PAR 4 APs (10) and with PAR 2 -APs (21) has demonstrated the caution with which such response data must be interpreted. Our principal finding with the canine coronary tissue was that the receptor conferring a contractile response appears distinct from PAR 2 that we detect either in the coronary endothelium or in MDCK cells based on two principal observations. First, the peptide trans-cinnamoyl-LIGRLO-NH 2 was an agonist in the relaxation and MDCK calcium signaling assays but an antagonist for SLIGRL-NH 2 in the contractile assay. The antagonist activity was selective for the action of SLIGRL-NH 2 , since contractions caused by TFLLR-NH 2 were not affected. Second, the relative order of potencies for the peptides in the coronary contractile assay (SLIGRL-NH 2 Ͼ Ͼ 2-furoyl-LIGRLO-NH 2 Ͼ Ͼ SLIGKT-NH 2 , with trans-cinnamoyl-LIGRLO-NH 2 an inactive antagonist) differed substantially from the relative order of potencies of these same peptides in the MDCK calcium assay, which we believe best reflects the pharmacology of canine PAR 2 (2-furoyl-LIGRLO-NH 2 Ͼ Ͼ SLIGRL-NH 2 ϭ trans-cinnamoyl-LIGRLO-NH 2 Ͼ Ͼ SLIGKT-NH 2 ). This order of agonist peptide potencies observed in the MDCK cells is the same as the one that has been previously observed for PAR 2 in a variety of intact tissues and cultured cells coming from several species, including the mouse, human, and rat (11, 23) . In the MDCK calcium signaling assay, trans-cinnamoyl-LIGRLO-NH 2 appeared to be a full agonist, and, in the endothelium-intact coronary preparation, the action of this peptide paralleled that of SLIGRL-NH 2 as shown with endothelium-intact rat vascular tissue (4, 11) . This relaxation response to SLIGRL-NH 2 and trans-cinnamoyl-LIGRLO-NH 2 is in keeping with the presence of PAR 2 mRNA in the coronary tissue, although the relative amount of PAR 2 mRNA in the endothelium vs. the smooth muscle elements was not determined. Unfortunately, it was not possible to obtain reliable concentration-effect curves for the relaxant actions of Shown are selected sequence information for the cleavage-activation tethered ligand sequence and other sequences (intracellular loops 1 to 4 and extracellular loop 2) involved in either tethered ligand or proteinase-activated receptor-2 activating peptide (PAR2-AP)-mediated cellular signaling. Sequences in this table can be compared with the available National Center for Biotechnology Information database (XM 546057) sequence for canine PAR2, which appeared after the completion of our sequencing work. Top sequences show the tethered ligand sequence, with the receptor-activating portion underlined, and the COOH-terminal cysteine (underlined) palmitoylation target, which when acylated can generate the fourth intracellular receptor loop.
the PAR 2 -APs to establish further, pharmacologically, the presence of functional PAR 2 in the intact coronary tissue.
In addition to differing from a potency order expected of PAR 2 , the order of PAR 2 -AP potencies in the contractile assay also differed substantially from the one thought to reflect activation of the NK 1 receptor by PAR 2 -related peptides in murine tracheal preparations (1) . Moreover, the distinct actions of substance P (relaxant at all concentrations tested) and SLIGRL-NH 2 (contractile at high concentrations) ruled out an action of the PAR 2 -derived peptides at the canine NK 1 receptor. This result was complemented by the lack of effect of either the NK 1 or the bradykinin B 1 /B 2 receptor antagonists on the contractile action of SLIGRL-NH 2 .
What mechanism might account for the very distinct PAR 2 SAR pharmacology for the receptor responsible for the contractile response in the coronary preparation, compared with the "classical" peptide SAR pharmacology of the PAR 2 -APmediated calcium response in the MDCK cells? Given the very close sequence homology between canine, human, and rat PAR 2 (Table 1) , it is unlikely that the distinct pharmacology for the PAR 2 -APs to cause contraction can be attributed to differences in the PAR 2 receptor sequences (canine vs. human or other). If anything, the canine receptor is closest to the human one, with a glycosylation site present just before the cleavage/activation site, a lysine at position 5 of the tethered receptor-activating ligand, and close homology in the predicted extracellular and intracellular loop sequences thought to confer responsiveness either to the tethered ligand or to the peptide agonists.
One possibility is that the different potency order observed in the coronary ring contraction assay, compared with the MDCK calcium signaling assay, might result from a novel receptor with extracellular loops in common with PAR 2 , although extensive differences elsewhere. Although PARs other than PAR 1 , PAR 2 , PAR 3 , and PAR 4 are not to be found in the human or canine genome, it is feasible that an as-yet unknown but PAR-related receptor is present in the canine genome to account for the "contractile" receptor system in the coronary. Although unlikely, given the lack of introns within the PAR gene portion coding for the tethered ligand and signaling portion of the receptors, the data might also be explained by a PAR splice variant. In this regard, the lack of dependence of the contractile response on either a prostanoid (resistance to and potentiation by indomethacin) or a Src kinase signal pathway (resistance to PP1) would distinguish signaling by this unknown receptor from signaling by the PARs in smooth muscle tissue, which has been found to be blocked by inhibitors of either tyrosine kinases or cyclooxygenase (18, 37, 38) .
Apart from a PAR family-related receptor (splice variant or other distinct but related sequence), our data rule out the NK 1 and bradykinin B 1 /B 2 receptors as targets for the PAR 2 -derived peptides. Our results therefore contrast with the situation described for the murine epithelial NK 1 receptor, which appears to be triggered by PAR 2 -related peptides to activate chloride transport (1) . Another possibility is that the coronary contractile response may be due to the activation PAR 2 heterodimers, akin to those now known to exist for PAR 1 and PAR 4 in human platelets and to exist for many G-protein-coupled receptors (19) . Should such heterodimers exist, involving PAR 2 and one or more of PAR 1 , PAR 3 , and PAR 4 , the overall pharmacology of heterodimer activation could well differ from that observed in a homodimer situation that may exist in cells like MDCK, wherein a PAR 1 response (and presumably PAR 1 itself) is minimal (Fig. 5, bottom right) and PAR 4 appears to be absent. Heterodimer formation involving PAR 1 and PAR 4 might also provide a rationale for the distinct endothelial receptors for thrombin detected on canine venous vs. arterial ring preparations (32) . The presence of a novel PAR 2 -AP-responsive receptor that could in principle form PAR dimers may be of clinical importance in the setting of ischemia-reperfusion, wherein PAR 2 has been found to be upregulated so as to contribute to a reduction in myocardial injury (25) . Although we have yet to obtain evidence for or against the formation of PAR 2 dimers, this hypothesis merits further exploration in the context of a receptor expression system, possibly using the MDCK cell background. In such a study, it will be important to look for SARs such as the one that we have observed here for the canine coronary tissue. Fig. 7 . Analysis of mRNA for PAR2 and PAR1 in coronary, ventricular, lung, and intestinal tissue. Samples were obtained from heart [descending coronary artery (DCA) and ventricle], lung, and intestinal tissues, quick frozen, and then processed for RT-PCR analysis as described in MATERIALS AND METHODS. A: gels of ethidium bromide signals visualized for PAR1, PAR2, and ␤-actin. B: abundance of mRNA for the PARs, relative to that for ␤-actin, as determined by scanning densitometry. Error bars show SE for n ϭ 3.
In summary, our structure-activity data point to a novel contractile receptor system for the PAR 2 -APs in the canine coronary preparation. Irrespective of the mechanism that may account for this unusual receptor system and its unprecedented SAR relationships for the PAR 2 -APs, the results do bear on the development of PAR 2 -targeted therapeutic agents in the future. Such PAR 2 agonists and antagonists are likely to prove of value in the setting of inflammatory and neurodegenerative disease (16, 27) . Thus, for PAR 2 -related drug development, in addition to the use of cell-based assays, it will be of importance to employ vascular tissue assays, especially those derived from human sources, to assess fully the pharmacology of potential therapeutic candidates.
